Abstract Higher plants continue to afford humankind with many new drugs, for a variety of disease types. In this review, recent phytochemical and biological progress is presented for part of a collaborative multi-institutional project directed towards the discovery of new antitumor agents. The specific focus is on bioactive natural products isolated and characterized structurally from tropical plants collected in Vietnam. The plant collection, identification, and processing steps are described, and the natural products isolated from these species are summarized with their biological activities.
Introduction
Cancer is the second leading cause of mortality in the United States, after heart disease, and is responsible for about one out of every four deaths (American Cancer Society 2013) . According to the most recent United States mortality data, 567,628 people died of cancer in 2009, with this being the main cause of death for persons between the ages of 40-79 years (Siegel et al. 2013) . It is estimated that in the year 2013, 1,660,290 new cancer cases will be diagnosed and about 580,350 Americans will die of cancer, accounting for approximately 1,600 deaths per day (American Cancer Society 2013; Siegel et al. 2013) . Cancer of the lung and bronchus is responsible for the greatest number of deaths, followed by prostate cancer for men or breast cancer for women, and colorectal cancer (American Cancer Society 2013; Siegel et al. 2013 ). However, cancer death rates have decreased slightly each year by about 1.8 % for men and by 1.5 % for women, according to the most recent statistics (2005) (2006) (2007) (2008) (2009) ) from the Surveillance, Epidemiology, and End Results (SEER) Program of the U. S. National Cancer Institute (Siegel et al. 2013) . The decrease in number of deaths due to cancer has been a result of adopting healthier lifestyles, and from the earlier detection of certain cancers by routine prevention screening, as well as improvements in treatment (American Cancer Society 2013; Siegel et al. 2013) .
Natural products play an important role in the treatment of cancer and disease in general. The origin of all approved drugs between the years 1981 and 2010 indicates that 4 % are unmodified natural products and 22 % are semi-synthetic derivatives (Newman and Cragg 2012) . Among cancer chemotherapeutic agents, the proportion of natural product-derived drugs is much more prevalent. According to recent data on approved antitumor agents from the 1930s to mid-2012, 16 % are unmodified natural products, and 31 % are semi-synthetic modifications of natural product compounds (Newman and Giddings 2013) . Natural product drugs may be sourced equally effectively from fungi, marine organisms, microorganisms, plants, and terrestrial animals (Cragg et al. 2009; Kinghorn et al. 2009; Newman and Giddings 2013; Pan et al. 2012a) .
The wide use of natural compounds as drugs is based on the structural variety and evolutionary biological roles of compounds isolated from Nature, when compared with synthetic compounds and those produced by combinatorial chemistry (Appendino et al. 2010; Cragg et al. 2009; Feher and Schmidt 2003; Kinghorn et al. 2009; Lachance et al. 2012; Pan et al. 2012a) . Secondary metabolites are products of enzymatic reactions by an organism or symbiotic consortium, and therefore tend to be intrinsically bioactive and complementary to their target macromolecules. As protein domains are highly conserved, secondary metabolites produced by an organism (e.g., a plant) have been found frequently to be complementary to animal protein targets, explaining the molecular basis for the intrinsic bioactivity of natural compounds (Appendino et al. 2010; Cragg et al. 2009; Kinghorn et al. 2009 ). Today, synthetic chemists often use lead bioactive natural products as ''privileged structures'' to build libraries of related compounds for further study (Appendino et al. 2010; Cragg et al. 2009; Feher and Schmidt 2003; Kinghorn et al. 2009; Lachance et al. 2012; Pan et al. 2012a) . It is estimated that 40 % of the pharmacophores found in natural product compounds are absent in synthetic compounds (Appendino et al. 2010 ). In addition, natural compounds have less rotatable bonds, a greater number of fused rings, bridgehead carbon atoms, and chiral centers, and are more oxygen-rich and contain less nitrogen, sulfur and halogen atoms than synthetic compounds (Appendino et al. 2010; Feher and Schmidt 2003; Kinghorn et al. 2009; Lachance et al. 2012; Pan et al. 2012a) . Moreover, the chemical space covered by natural compounds is much larger than the chemical space occupied by synthetic compounds, and is very similar to the chemical space of approved drugs (El-Elimat et al. 2012; Feher and Schmidt 2003) .
The Kingston et al. 2012; Lucas et al. 2010; Pan et al. 2012a; Rahier et al. 2005) . Table 1 presents a comprehensive subset of U.S. FDA new drug application (NDA) approvals from the period January 1, 2011 to June 30, 2013, comprising unmodified natural products isolated from plants, synthetic derivatives of plant natural products, and a refined plant extract marketed as a ''botanical drug product''. This table builds on a similar tabulation from a previous review that summarized plant-derived drugs approved during the period 2001 . The ''botanical drug product'' Fulyzaq Ò (crofelemer), introduced in 2012, is a mixture of oligomeric proanthocyanidins from Croton lechleri Müll. Arg. (Euphorbiaceae), and used for the treatment of diarrhea associated with HIV/AIDS antiretroviral therapy. As described for Veregen Ò , the only prior example of a botanical drug product approved by the FDA in 2006, strict quality control, standardization and clinical trial protocols were required prior to NDA approval of Fulyzaq Ò (Chen et al. 2008) . With roughly 500 current investigational new drugs (INDs) or pre-IND applications for botanical drug products now being considered, this appears to be a new drug category with a meaningful future potential (Dou 2013 Likewise, these same types of NDAs were omitted from Fig. 1 , which is a graphical illustration of the source of all new drugs approved by the U.S. FDA during calendar year 2012. This shows that, if botanicals are included, 10 % of 2012 new drug approvals were produced with minor modification or directly from plants, 27.5 % from terrestrial animals, 12.5 % from bacteria, 2.5 % from marine sources, and Ò (eicosapentaenoic acid methyl ester), which is included above. For simplicity, bacterial and human proteins approved as biological drugs were considered as bacterial and animal natural products, respectively 47.5 % entirely synthetically. This figure summarizes in a clearly discernible fashion the current net impact of ongoing natural products research on the development of new drugs. This is particularly significant during an era in which natural products research has been discontinued or curtailed by financial cutbacks evident in the pharmaceutical industry, with the void filled by smaller companies, as well as by academic and government laboratories (Kingston 2011) . The remainder of this review summarizes several promising anticancer lead compounds that have been isolated from plants collected in Vietnam as part of the multi-institutional collaborative research falling under the program project P01 CA125066 entitled ''Discovery of Anticancer Agents of Diverse Natural Origin''. The funding for this project was provided by the U.S. National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD. The aim of this research is the discovery of new natural product anticancer lead compounds from tropical plants, filamentous fungi, and aquatic cyanobacteria. The program project integrates the research work of three academic institutions (University of Illinois at Chicago, University of North Carolina at Greensboro, and The Ohio State University), a biotechnology company (Mycosynthetix, Inc., Hillsborough, North Carolina), and a pharmaceutical partner (Brystol-Myers Squibb, Princeton, New Jersey) Orjala et al. 2012) . Herein, the results are reported of the bioactivityguided isolation of anticancer lead compounds from Vietnamese tropical plants discovered in our laboratories at The Ohio State University and the University of Illinois at Chicago over the last few years.
Botanical collections
Altogether, 824 primary plant samples corresponding to 398 species were collected during several plant collection expeditions to Vietnam carried out during the period 2008-2011. Plant specimens were collected as part of a Memorandum of Agreement between the University of Illinois at Chicago and the Institute of Ecology and Biological Resources of the Vietnam Academy of Science and Technology, Hanoi, Vietnam. Plant parts under evaluation have been the bark, flowers, fruits, leaves, roots, stems, and twigs, either singly or in various combinations. The natural products database, NAPRALERT TM was used for the selection of endemic, phytochemically underexplored plants in Vietnam for study (Loub et al. 1985) . The ''Indo-Burma'' region inclusive of Vietnam was chosen for plant collections since it is considered a ''global biodiversity hotspot'', containing about 44 % of the world's plant species but covering only 1.4 % of the land area (Malcolm et al. 2006; Rai and Lalramnghinglova 2011 
Compounds isolated
From the plants collected in Vietnam and investigated phytochemically thus far, 17 new and 42 known compounds were found to have in vitro activity in one or more bioassays, exhibiting IC 50 values of less than 10 lM ( Fig. 2 ; Table 2 ). In some cases promising lead compounds have been evaluated against biological targets other than those strictly germane to cancer chemotherapeutic drug discovery. The isolation procedures for the new compounds, perviridisin B (1), a cyclopenta[b]benzopyran analogue purified from Aglaia perviridis and elaeocarpucin C (32), a 16,23-epoxycucurbitacin derivative obtained from Elaeocarpus chinensis, were directed by LC/MS dereplication and cytotoxicity-guided fractionation using HT-29 human colon cancer cells (Pan et al. 2012b . The structure elucidation of the structurally interesting compound, perviridisin B (1), was based on extensive NMR data interpretation. Compound 1 exhibited 11 downfield proton signals in the 1 H-NMR spectrum, characteristic of a cyclopenta[b]benzopyran backbone, similar to the values described for previously reported compounds (Inada et al. 2001; Pan et al. 2013) . In addition, the 1 H-and 13 C-NMR spectra skeleton. The C-10 epimer of 1 was also isolated in this study; however, this epimer showed no discernible biological activity ). Potent (Pan et al. 2012b . In addition, compound 1 showed no toxicity to CCD112CoN normal human colon cells . A new caged xanthone, cochinchinoxanthone (20), was found to be cytotoxic against the HT-29 cell line and has activity in a mitochondrial transmembrane potential (MTP) assay, with IC 50 values of 5.8 and 3.3 lM, respectively (Ren et al. 2011) . The structure elucidation of 20 was based on spectroscopic data interpretation and comparison of its NMR spectra to those reported for similar caged xanthones (Thoison et al. 2000; Ren et al. 2010) . Also, the UV (k max 226, 327, 346 nm), and IR (m max 1,744 and 1,644 cm -1 ) data, and three quaternary carbon peaks at d C 84.0 (C-5), 84.7 (C-13) and 90.3 (C-10 a ) ppm, were diagnostic signals used to propose a caged xanthone structure (Ren et al. 2011) .
Three new flavanones, (?)-5-methoxypurpurin (40), (2S)-2,3-dihydrotephroglabrin (41), and (2S)-2,3-dihydrotephroapollin C (42), isolated from Indigofera spicata, showed cancer chemopreventive potential by inducing quinone reductase activity, a phase II metabolizing enzyme, in Hepa 1c1c7 murine hepatoma cells (Bueno Pérez et al. 2013) . The structures of the new compounds were determined by NMR data interpretation and comparison of their chemical shifts to the values of closely related analogues reported previously in the literature (Abd El-Razek et al. 2007; Rao and Raju 1984; Waterman and Khalid 1980) . In addition, the 1 H-NMR data of compounds 40-42 showed typical signals for the presence of a flavanone nucleus with resonances around d H 5.5 (H-2), 2.9 (H-3 a ), and 3.0 (H-3 b ) ppm (Bueno Pérez et al. 2013) . The absolute configuration assignments were based on circular dichroism and specific rotation measurements. Compounds 40-43 and 48 were active with CD (concentration required to double quinone reductase activity) values of less than 10 lM and low toxicity to cells with IC 50 values greater than 20 lM (Bueno Pérez et al. 2013 ). In addition, compound 40 showed more potent induction activity with much lower toxicity to cells than the positive control, L-sulforaphane (CD = 0.5 lM, IC 50 = 12.1 lM, and CI = 23.9), a well-known monofunctional inducer of quinone reductase obtained from broccoli (Bueno Pérez et al. 2013; Zhang et al. 1992) .
Compounds that act upon neural nicotinic acetylcholine receptors (nAChRs) have attracted interest in drug discovery for the potential treatment of autism, cancer, depression and other diseases (Still et al. 2013) . A new piperidine alkaloid, microgrewiapine A (49), isolated from Microcos paniculata, showed cytotoxicity to HT-29 cells with an IC 50 value of 6.8 lM and also modulated the activity of two nAChRs (Still et al. 2013 ). The structure determination of 49 was based on extensive spectroscopic data interpretation. The relative configuration of substituents at positions C-2 and C-6 was proposed based on determination of coupling constants and 1 H-1 H NO-ESY correlations, whereas the R-absolute configuration at the C-3 hydroxy group was assigned using the Mosher ester reaction (Still et al. 2013) . Compound 49 exhibited selective cytotoxicity against HT-29 cells when compared to CCD-112CoN normal cells, and also displayed antagonistic activity with 60 and 70 % inhibition against the ha4b2 and ha3b4 nAChRs, respectively (Still et al. 2013) . Microgrewiapine A (49) is also the first example of a cytotoxic and nAChR antagonist piperidine alkaloid to have been obtained from a plant in the genus Microcos (Still et al. 2013) .
The known compounds rocaglaol (7), methyl rocaglate (8) and five other known rocaglate derivatives (4-6, 9-10), four known cucurbitacins, cucurbitacin D (36), 3-epi-isocucurbitacin D (37), 25-Oacetylcucurbitacin F (38), cucurbitacin I (39), and two known rotenoids, cis-(6ab,12ab)-hydroxyrotenone (44) and rotenone (45), were also found to exhibit potent cytotoxicity against HT-29 cells with IC 50 values of less than 1 lM (Bueno Pérez et al. 2013; Pan et al. 2012b Pan et al. , 2013 . Compounds 5 and 9 showed particularly potent activity against HT-29 cells with IC 50 values of 0.002 and 0.0007 lM, respectively, and were comparable in potency to the positive control, paclitaxel, which gave an IC 50 value of 0.001 lM ). In addition, compounds 4-10 and 44-45 were selective for HT-29 cells when compared with CCD-112CoN normal human colon cells (Bueno Pérez et al. 2013; Pan et al. 2012b) . In a collaborative study, cucurbitacin D (36) was found to potently inhibit cell growth of neurofibromatosis type 2 (NF2)-deficient mouse schwannoma (Sch10545) and human benign meningioma (Ben-Men-1) cells, with IC 50 values of 0.8 and 0.2 lM, respectively (Spear et al. 2013) . It was also found that compound 36 inhibited the expression of cyclins A, B, and E, in addition to reducing the levels of phosphorylated AKT and PRAS40 (Spear et al. 2013) . The known quassinoids bruceantin (17) and bruceine A (18) were highly active against the human cancer cell lines Lu1 (lung), LNCaP (hormone-dependent prostate), and MCF-7 (breast), with IC 50 values in the nanomolar range, whereas rotenoids 44-45 exhibited significant growth inhibition against 697 human acute lymphoblastic leukemia cells with IC 50 values of \1 lM (Bueno Pérez et al. 2013; Pan et al. 2009 ).
Prolonged activation of nuclear factor jB (NF-jB) and proteasome activity, as well as decreased apoptosis, are some of the molecular changes directly correlated with oncogenesis (Deng et al. 2009; Gatti et al. 2013; Kim et al. 2006) . Therefore, the inhibition of NF-jB activation, proteasome inhibition and loss of mitochondrial transmembrane potential (MTP), associated with cell death, were also investigated. The activation of NFjB (p65) was strongly inhibited by compound 4 (IC 50 value of 0.3 lM) as well as 7 and 12 (both with IC 50 values of 0.005 lM), in addition to elaeocarpucin C (32) (IC 50 value of 2.4 lM) (Pan et al. 2012b . The coumarin, barbatumol A (16), and the xanthone, amangostin (21), potently induced apoptosis through the disruption of mitochondrial transmembrane potential, with IC 50 values of 0.5 and 0.2 lM, respectively (Pan et al. 2011b; Ren et al. 2011) .
The cytotoxicities of bruceantin (17) and bruceine A (18) against MCF-7 cells were enhanced about 10-fold when combined with the flavonolignan (-)-hydnocarpin (19), isolated from Brucea javanica (Pan et al. 2009 ). In a similar way, (-)-hydnocarpin (19) at 10 lM also produced a significant potentiating effect in vincristine cytotoxicity at concentrations of 1.5 and 0.75 nM against 697 cells resulting in 83 % (p = 0.03) and 61 % (p \ 0.0001) increase in growth inhibition, respectively, when compared to vincristine treatment alone. Furthermore, (-)-hydnocarpin (19), at doses of 10 and 5 lM, was able to reverse resistance to vincristine treatment, causing 72 % (p B 0.0001) and 41 % (p = 0.03) growth inhibition, respectively, in 697-R human acute lymphoblastic leukemia multidrug-resistant cells overexpressing P-glycoprotein (P-gp) (Bueno Pérez et al. 2012) .
In addition to the new flavanones 40-42 with potential cancer chemopreventive activity, a known flavanone (43), a rotenoid, tephrosin (46), and a chalcone, (?)-tephropurpurin (47), isolated from I. spicata, together with a semi-synthetic chalcone, (?)-tephrosone (48), were active with CD values of less than 10 lM and low toxicity to Hepa 1c1c7 cells with IC 50 values greater than 10 lM (Bueno Pérez et al. 2013) . Moreover, tephrosin (46) showed slightly more potent induction activity than the positive control, L-sulforaphane with a CD value of 0.4 lM, and lower toxicity to Hepa 1c1c7 cells, with an IC 50 value of 13.9 lM and a CI value of 35.3 (Bueno Pérez et al. 2013) .
The mechanism by which dichamanetin (57), a Cbenzylated flavanone isolated from Piper sarmentosum, exerts its cytotoxic action was investigated using HT-29, MDA-MB-231 human breast cancer and PC3 human prostate cancer cell lines . Dichamanetin (57) at 25 lM produced cell cycle arrest, particularly in MDA-MB-231 cells, causing inhibition of cell cycle progression past G1 in about 70 % of treated cells ). Activation of NF-jB has been linked to IJB kinase enzyme (IKK) complex, which regulates the NF-jB signal cascade (Kim et al. 2006) . Compound 57 inhibited both IKK and NF-jB expression ). In addition, dichamanetin (57) binds to DNA and affects the mitochondrial transmembrane potential .
The ultimate goal of our project is the discovery of new antitumor agents from tropical plants, so therefore promising cytotoxic lead compounds with high selectivity towards cancer cells are tested further in a rapid, efficient and cost effective in vivo system, the hollow fiber assay (Mi et al. 2009; Pearce et al. 2012) . The in vivo hollow fiber assays were performed using three human cancer cell lines (HT-29, MCF-7 and MDA-MB-435 melanoma) enclosed in hollow fibers and implanted intraperitoneally (ip) and subcutaneously (sc) in immunodeficient mice (Mi et al. 2009 ). The new compound, elaeocarpucin C (32), and the known compounds, 3,6-di-O-acetyl-a-mangostin (26) as well as cis-(6ab,12ab)-hydroxyrotenone (44), were chosen for in vivo testing due to their high cytotoxic potencies and high selectivities against HT-29 cells (Bueno Pérez et al. 2013; Pan et al. 2012b; Ren et al. 2011) . Semi-synthesis of elaeocarpucin C (32) was performed using a closely related 16,23-epoxycucurbitacin analogue to produce sufficient amounts of this potent compound (IC 50 value of 0.4 lM against HT-29 cells) for evaluation in the hollow fiber assay (Pan et al. 2012b) . The known compounds, 3,6-di-O-acetyla-mangostin (26) and cis-(6ab,12ab)-hydroxyrotenone (44) also exhibited potent in vitro cytotoxicities, with IC 50 values of 1.0 and 0.1 lM, respectively, against HT-29 cells (Bueno Pérez et al. 2013; Ren et al. 2011) . Compounds 26 and 32 produced no cell growth inhibition in the hollow fiber assay with any of the cell lines or doses under study (Pan et al. 2012b; Ren et al. 2011) . cis-(6ab,12ab)-Hydroxyrotenone (44) was lethal to mice at the high doses of 30, 15, 10 and 5 mg/kg. Therefore, compound 44 was further assayed at the low doses of 2, 1, and 0.5 mg/kg, but this resulted in only a 20 % reduction in cell growth for MDA-MB-435 cells at a dose of 2 mg/kg (Bueno Pérez et al. 2013 ).
Conclusions
The results of this collaborative research project show that tropical plants continue to provide numerous chemically diverse secondary metabolites with activity and selectivity for cancer cells. Some of these natural product lead candidates discovered through bioactivity-guided fractionation might serve as scaffolds for synthetic modifications to potentially develop them as new anticancer agents. The work in this project has been predicated on the collaborative efforts of a multidisciplinary team comprised of biologists, natural products chemists, and plant taxonomists. 
